Ganciclovir-mediated in vivo elimination of myeloid leukemic cells expressing the HSVtk gene induces HSVtk loss variants

Gene Therapy

Volumn 6, Issue 6, 1999, Pages 1139-1146

  Braakman, E ^a,b   Vogels, R ^c,d   Martens, A C M ^e   Vermeulen, J ^a,b   Bron, M ^b   Hoogerbrugge, P M ^f   Valerio, D ^c,d   Hagenbeek, A ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c CRUCELL HOLLAND BV   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bystander cell killing; Herpes simplex virus thymidine kinase; Immuno(gene)therapy; Leukemia

Indexed keywords

GANCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CISTRON; GENE EXPRESSION; HERPES SIMPLEX VIRUS; LEUKEMIA CELL; MALE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; RAT; RETROVIRUS; SUICIDE GENE; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; GANCICLOVIR; GENE THERAPY; IMMUNOTHERAPY; LEUKEMIA, MYELOID; NEOPLASM TRANSPLANTATION; RATS; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

ANIMALIA; DNA VIRUSES; HERPES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0032981983     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300913     Document Type: Article

References (32)

1. Tepper RI, Mulé JJ. Experimental and clinical studies of cytokine gene modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
2. Forni G et al. Molecular approaches to cancer immunotherapy. Cytokines Mol Ther 1995; 1: 225-248.
3. Farzaneh F, Trefzer U, Sterry W, Walden P. Gene therapy of cancer. Immunol Today 1998; 19: 294-296.
4. Hock H et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 1993; 53: 714-716.
5. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
6. Santodonato L et al. Cure of mice with established metastatic friend leukemia tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
7. Furman PA et al. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Virology 1980; 102: 420-430.
8. Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975; 21: 113-130.
9. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
10. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
11. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res 1994; 54: 1503-1506.
12. Yamamoto S et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther 1997; 4: 91-96.
13. Freeman SM et al. The 'bystander effect': tumor regression when only a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
14. Huber BE et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302-8306.
15. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.
16. Bi WL, Parysek LM, Warnck R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
17. Colombo BM et al. The 'bystander effect': association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.
18. Samejima Y, Meruelo D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Therapy 1995; 2: 50-58.
19. Tiberghien P et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T cell depletion after bone marrow transplantation? Blood 1994; 84: 1333-1341.
20. Rogers RP et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther 1996; 7: 2235-2245.
21. Trinh QT et al. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995; 55: 4808-4812.
22. Mesnil M et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
23. Golumbek PT et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live nonimmunogenic tumor cell vaccines. J Immunother 1992; 12: 224-230.
24. Yang L et al. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin Cancer Res 1998; 4: 731-741.
25. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
26. Benedetti S et al. Limited efficacy of the HSVtk/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther 1997; 8: 1345-1353.
27. Vrionis FD et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Therapy 1997; 4; 577-585.
28. Mesnil M, Piccoli C, Yamasaki H. A tumor suppressor gene, Cx26, also mediates bystander effect in HeLa cells. Cancer Res 1997; 57: 2929-2932.
29. Hughes BW et al. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem 1998; 273: 2322-2328.
30. Martens AC, van Bekkum DW, Hagenbeek A. The BN acute myelocytic leukemia (BNML), a rat model for studying human acute myelocytic leukemia (AML). Leukemia 1990; 4: 241-257.
31. Van Beusechem VW et al. Expression of human adenosine deaminase in mice transplanted with hemopoietic stem cells infected with amphotropic retroviruses. J Exp Med 1990; 172: 729-736.
32. Van Beusechem VW, Kukler A, Heidt PJ, Valerio D. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. Proc Natl Acad Sci USA 1992; 89: 7640-7644.